Neointimal coverage with Everolimus-eluting Bioresorbable Scaffolds at the coronary bifurcation lesions using optical coherence tomography (OCT).
Phase of Trial: Phase II
Latest Information Update: 11 Feb 2016
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Pharmacodynamics
- 11 Feb 2016 New trial record